Scientist writing results in lab_cropped.jpg

Published Papers

Supporting the Ex-Vivo Analysis of Programmed Cell Death functional profiling assay

Since founding Rational Therapeutics (now Nagourney Cancer Institute) over 20 years ago, Dr. Nagourney, his team and colleagues have published a number of papers supporting the use of the Ex-Vivo Analysis of Programmed Cell Death (EVA-PCD) functional profiling assay, as well as the effectiveness of new drugs and combinations.

Dr. Nagourney himself has AUTHORED more than 100 manuscripts, book chapters and abstracts including publications in the JOURNAL OF CLINICAL ONCOLOGY, GYNECOLOGIC ONCOLOGYTHE JOURNAL OF THE NATIONAL CANCER INSTITUTE. and BRITISH JOURNAL OF CANCER.

We have selected a few of our most prominent papers to make available for download on this site.


Survival Curves

Comparing the survival of patients who tested sensitive to the agents they received, compared with those who were found resistant to the treatments that they received.

Clinical Application of Assay-Directed Therapy

Predicted clinical outcomes for patients treated with agents found active in the laboratory using the EVA-PCD functional profile.

Physician Information

Find out how you can receive specific information on how your patient’s cancer cells will react to single agents, combinations or targeted therapies.